{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=7",
    "query": {
      "condition": "Diagnosis of Melanoma",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 1869,
    "total_pages": 187,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diagnosis+of+Melanoma&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T00:09:51.596Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00027586",
      "title": "Imatinib Mesylate in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Skin Neoplasms"
      ],
      "interventions": [
        {
          "name": "Imatinib mesylate (STI571)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 22,
      "start_date": "2001-09",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2018-10-31",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027586"
    },
    {
      "nct_id": "NCT02363283",
      "title": "Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Uveal Melanoma",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Glembatumumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2015-09-16",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02363283"
    },
    {
      "nct_id": "NCT03470922",
      "title": "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 714,
      "start_date": "2018-04-11",
      "completion_date": "2030-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Luis Obispo, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Luis Obispo",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03470922"
    },
    {
      "nct_id": "NCT03873818",
      "title": "Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-02-21",
      "completion_date": "2025-08-21",
      "has_results": true,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03873818"
    },
    {
      "nct_id": "NCT00089362",
      "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Breast Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Gastric Cancer",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Melanoma",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Basal Cell Carcinoma of the Lip",
        "Stage III Colon Cancer",
        "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Gastric Cancer",
        "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Lymphoepithelioma of the Nasopharynx",
        "Stage III Lymphoepithelioma of the Oropharynx",
        "Stage III Melanoma",
        "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Gastric Cancer",
        "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Melanoma",
        "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Untreated Metastatic Squamous Neck Cancer With Occult Primary"
      ],
      "interventions": [
        {
          "name": "alvespimycin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-04-10",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089362"
    },
    {
      "nct_id": "NCT00288041",
      "title": "Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ciliary Body and Choroid Melanoma, Medium/Large Size",
        "Extraocular Extension Melanoma",
        "Iris Melanoma",
        "Recurrent Intraocular Melanoma",
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-05",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288041"
    },
    {
      "nct_id": "NCT07556380",
      "title": "Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)"
      ],
      "interventions": [
        {
          "name": "UV Real-Time Alerts",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Track Your Sun Protection",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Current Conditions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Coaching",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Action Planning",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Core Components",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-04-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07556380"
    },
    {
      "nct_id": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Merkel Cell Carcinoma",
        "Cutaneous T-Cell Lymphoma",
        "Melanoma",
        "Renal Cancer",
        "Bladder Cancer",
        "Prostate Cancer",
        "Testicular Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02643303"
    },
    {
      "nct_id": "NCT00700882",
      "title": "Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2009-07-02",
      "completion_date": "2020-12-28",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 153,
      "location_summary": "Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00700882"
    },
    {
      "nct_id": "NCT01721603",
      "title": "Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAFV600E Melanoma Patients"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Gamma Knife Radiosurgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-04",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-23T00:09:51.596Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721603"
    }
  ]
}